beta
Trial Radar AI
Clinical Trial NCT07485569 (REPOTHYROID-II) for Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial (REPOTHYROID-II) Phase 1 10 Personalized Treatment

Not yet recruiting
Clinical Trial NCT07485569 (REPOTHYROID-II) is designed to study Treatment for Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma. This Phase 1 interventional study is not yet recruiting. Enrollment is planned to begin on 1 June 2026 until the study accrues 10 participants. Led by Radboud University Medical Center, this study is expected to complete by 1 September 2027. The latest data from ClinicalTrials.gov was last updated on 27 March 2026.
Brief Summary
This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible and safe to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments can help control the growth ...Show More
Detailed Description
Patients with advanced thyroid cancer often have very few treatment options, and standard therapies usually cannot cure the disease. Some types grow and spread quickly and do not respond to surgery and radioactive iodine. For patients with other types, existing drugs may slow the disease but can cause strong side effects, limiting their usefulness.

This study is testing a new personalized approach called network pha...

Show More
Official Title

Network Pharmacology-based Personalized Drug Repurposing in Thyroid Carcinoma: a Pilot Feasibility Trial

Conditions
Thyroid Cancer Stage IVAnaplastic Thyroid CancerDifferentiated Thyroid CancerPoorly Differentiated Thyroid Carcinoma
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • REPOTHYROID-II
  • 2023-507214-28-00
NCT ID Number
NCT07485569
Start Date (Actual)
2026-06-01
Last Update Posted
2026-03-27
Completion Date (Estimated)
2027-09-01
Enrollment (Estimated)
10
Study Type
Interventional
PHASE
Phase 1
Status
Not yet recruiting
Keywords
Drug repurposing
Thyroid cancer
Network pharmacology
Personalized therapy
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalPersonalized network-pharmacology-based combination therapy
Patients with advanced thyroid cancer undergo tumor molecular profiling using to identify personalized drug repurposing treatments. All drugs are administered at authorized therapeutic doses according to the summary of product characteristics. Treatment regimens vary between patients depending on the identified molecular profile.
Personalised treatment
The therapy will consist of (one or more) drugs listed below: * Tamoxifen * Selpercatinib * Indomethacin * Niclosamide * Sunitinib * Dabrafenib * Trametinib * Erlotinib * Simvastatin * Temozolomide
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Feasibility
Number and proportion of enrolled patients who initiate study treatment.
12 weeks
Safety
Number and proportion of patients who experience treatment-related adverse events (CTCAE v5.0).
12 weeks
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Preliminary efficacy
Disease control rate (DCR) at 3 months, defined as the number and proportion of patients achieving stable disease (SD), partial response (PR), or complete response (CR), according to RECIST 1.1.
12 weeks
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Patients with locally advanced or metastatic TC (such as ATC, PDTC, and RAI refractory DTC progressive under treatment with multikinase inhibitors) for whom no approved conventional treatments are available.
  • Prior anticancer treatment-related toxicities resolved to Grade ≤1 (CTCAE v5.0).
  • Measurable disease per RECIST 1.1
  • ECOG performance status ≤ 2
  • Negative pregnancy test within 7 days prior to starting the study in women of childbearing potential and adequate use of contraception.

  • Inability to provide informed consent
  • Inability to obtain a (new) biopsy for molecular profiling
  • Pregnancy or breastfeeding.
  • Other active malignancies requiring therapy.
  • Neutropenia (ANC < 1.5 × 10⁹/L).
  • Severe uncontrolled medical conditions (renal, cardiac, liver, respiratory).
Radboud University Medical Center logoRadboud University Medical Center
Study Central Contact
Contact: R Netea-Maier, Prof. Dr., +31243614599, [email protected]
No location data.